Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

New strategy heads at Genmab and Codagenix

Plus: OncoVerity names Colao CEO and Smith CMO, and updates from Silence, Mannkind, Immuneering and more

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
March 28, 2023 11:24 PM UTC

Genmab A/S (NASDAQ:GMAB; CSE:GMAB) promoted Martine van Vugt to chief strategy officer and EVP, effective March 29. van Vugt joined in 2001 as a program manager, and was most recently SVP of corporate strategy and planning. 

Viral vaccines and immuno-oncology company Codagenix Inc. hired Kimber Poffenberger as chief strategy officer. Poffenberger was principal consultant at Poffenberger Regulatory Resources, before which she was SVP, head of global regulatory affairs at Alvotech Holdings S.A. (NASDAQ:ALVO; XICE:ALVO). ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Avacta Group plc

Codagenix Inc.

Genmab A/S

Immuneering Corp.

Mannkind Corp.

OncoVerity Inc.

Silence Therapeutics plc

BCIQ Target Profiles

MAP kinase (MAPK) (ERK)